Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

Open access
Lassman, A. B., Iwamoto, F. M., Cloughesy, T. F., Aldape, K. D., Rivera, A. L., Eichler, A. F., Louis, D. N., Paleologos, N. A., Fisher, B. J., Ashby, L. S., Cairncross, J. G., Roldan, G. B., Wen, P. Y., Ligon, K. L., Schiff, D., Robins, H. I., Rocque, B. G., Chamberlain, M. C., Mason, W. P., Weaver, S. A., Green, R. M., Kamar, F. G., Abrey, L. E., DeAngelis, L. M., Jhanwar, S. C., Rosenblum, M. K., Panageas, K. S.·2011·Neuro-Oncology

Abstract

Treatment for newly diagnosed anaplastic oligodendroglial tumors is controversial. Radiotherapy (RT) alone and in combination with chemotherapy (CT) are the most well studied strategies. However, CT alone is often advocated, especially in cases with 1p19q codeletion. We retrospectively identified 1013 adults diagnosed from 1981-2007 treated initially with RT alone (n = 200), CT + RT (n = 528), CT alone (n = 201), or other strategies (n = 84). Median overall survival (OS) was 6.3 years and time to progression (TTP) was 3.1 years. 1p19q codeletion correlated with longer OS and TTP than no 1p or 19q deletion. In codeleted cases, median TTP was longer following CT + RT (7.2 y) than following CT (3.9 y, P = .003) or RT (2.5 y, P < .001) alone but without improved OS; median TTP was longer following treatment with PCV alone than temozolomide alone (7.6 vs. 3.3 y, P = .019). In cases with no deletion, median TTP was longer following CT + RT (3.1 y) than CT (0.9 y, P = .0124) or RT (1.1 y, P < .0001) alone; OS also favored CT + RT (median 5.0 y) over CT (2.2 y, P = .02) or RT (1.9 y, P < .0001) alone. In codeleted cases, CT alone did not appear to shorten OS in comparison with CT + RT, and PCV appeared to offer longer disease control than temozolomide but without a clear survival advantage. Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nor040

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 176

Metadata

Authors
Lassman, A. B., Iwamoto, F. M., Cloughesy, T. F., Aldape, K. D., Rivera, A. L., Eichler, A. F., Louis, D. N., Paleologos, N. A., Fisher, B. J., Ashby, L. S., Cairncross, J. G., Roldan, G. B., Wen, P. Y., Ligon, K. L., Schiff, D., Robins, H. I., Rocque, B. G., Chamberlain, M. C., Mason, W. P., Weaver, S. A., Green, R. M., Kamar, F. G., Abrey, L. E., DeAngelis, L. M., Jhanwar, S. C., Rosenblum, M. K., & Panageas, K. S.
Venue
Neuro-Oncology
Published
2011-06-01
Volume
13
Issue
6
Pages
649-659
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2106824860
Cited by
176
References
2
FWCI
7.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. https://app.cochat.ai/papers/10.1093/neuonc/nor040
The paper
Lassman, A. B., Iwamoto, F. M., Cloughesy, T. F., Aldape, K. D., Rivera, A. L., Eichler, A. F., Louis, D. N., Paleologos, N. A., Fisher, B. J., Ashby, L. S., Cairncross, J. G., Roldan, G. B., Wen, P. Y., Ligon, K. L., Schiff, D., Robins, H. I., Rocque, B. G., Chamberlain, M. C., Mason, W. P., . . . Panageas, K. S. (2011). International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/nor040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.